George Yancopoulos, Regeneron president and CSO (Regeneron)
Regeneron scores label expansion for cholesterol drug Evkeeza
Regeneron’s drug for a rare disease that causes high cholesterol has been expanded to include children ages 5 to 11 years old after an approval from the FDA.
The mAb Evkeeza, initially approved in Feb. 2021 as an adjunct to other lipid-lowering therapies in patients 12 years and older with the rare homozygous familial hypercholesterolemia (HoFH). It works by blocking the function of angiopoietin-like 3, a protein that plays a key role in lipid metabolism.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
